Rhythm reports Phase II data of setmelanotide to treat Bardet-Biedl Syndrome

In October, Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) reported preliminary data from 5 Bardet-Biedl Syndrome patients with morbid obesity and hyperphagia in the Phase II

Read the full 230 word article

User Sign In